Additional File 2. F	requency categories of adverse reactions reported in the pooled ana	lysis considered for the safety pooling.
Adverse reactions	are listed according to MedDRA system organ class and frequency cat	egory. Frequency categories are defined using the
following convention	on: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1	/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very
rare (<1/10,000). W	ithin each frequency grouping, adverse reactions are presented in ord	der of decreasing seriousness.
Infections and infe	stations	
Very common	Infections a,	
Blood and lymphatic system disorders		
Very common	Anaemia	

Thrombocytopenia, neutropenia, leukopenia, lymphopenia

Common

Uncommon	Pancytopenia			
Rare	Pure red cell aplasia			
Immune system disorders				
Uncommon	Hypersensitivity			
Metabolism and n	utrition disorders			
Very common	Decreased appetite, hyperglycaemia, hypercholesterolaemia			
Common	Hypertriglyceridaemia, hypophosphataemia, diabetes mellitus,			
	hyperlipidaemia, hypokalaemia, dehydration, hypocalcaemia			
Psychiatric disorde	ers			
Common	Insomnia			
Nervous system d	isorders			
Very common	Dysgeusia, headache			
Uncommon	Ageusia			
Eye disorders	1			
Common	Eyelid oedema			

Uncommon	Conjunctivitis					
Cardiac disorders						
Uncommon	Congestive cardiac failure					
Vascular disorders	Vascular disorders					
Common	Haemorrhage b, hypertension					
Uncommon	Flushing, deep vein thrombosis					
Respiratory, thoracic and mediastinal disorders						
Very common	Pneumonitis c, epistaxis					
Common	Cough, dyspnoea					
Uncommon	Haemoptysis, pulmonary embolism					
Rare	Acute respiratory distress syndrome					
Gastrointestinal disorders						
Very common	Stomatitis d, diarrhoea, nausea					
Common	Vomiting, dry mouth, abdominal pain, mucosal inflammation, oral					
	pain, dyspepsia, dysphagia					

Hepatobiliary dis	orders		
Common	Aspartate aminotransferase increased, alanine aminotransfera increased		
Skin and subcuta	neous tissue disorders		
Very common	Rash, pruritus		
Common	Dry skin, nail disorders, mild alopecia, acne, erythema,		
	onychoclasis, palmar-plantar erythrodysaesthesia syndrome, skin		
	exfoliation, skin lesion		
Rare	Angioedema		
Musculoskeletal	and connective tissue disorders		
Common	Arthralgia		
Renal and urinary	y disorders		
Common	Proteinuria, blood creatinine increased, renal failure		
Uncommon	Increased daytime urination, acute renal failure		
Reproductive sys	tem and breast disorders		

Common	Menstruation irregular e				
Uncommon	Amenorrhoea e				
General disorders and administration site conditions					
Very common	common Fatigue, asthenia, peripheral oedema				
Common	Pyrexia				
Uncommon	Non-cardiac chest pain				
Rare	Impaired wound healing				
Investigations					
Very common	Weight decreased				

a Includes all reactions within the 'infections and infestations' system organ class including (common) pneumonia and (uncommon) herpes zoster, sepsis, and isolated cases of opportunistic infections [e.g. aspergillosis, candidiasis, pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) and hepatitis B (see also section 4.4)]

b Includes different bleeding events not listed individually

c Includes (common) pneumonitis, interstitial lung disease, lung infiltration and (rare) pulmonary alveolar haemorrhage, pulmonary toxicity, and alveolitis

d Includes (very common) stomatitis, (common) aphthous stomatitis, mouth and tongue ulceration and (uncommon) glossodynia, glossitis e Frequency based upon number of women from 10 to 55 years of age in pooled data